Michael E. Chernew

Michael E. Chernew

Auto-generated profile, based on publicly available information

Michael E. Chernew

Department of Health Care Policy Harvard Medical School Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Health Affairs
Verified
Journal Article
Closed access
PDF file
MCMichael E. Chernew
Michael E. Chernew
ARAllison B. Rosen
Allison B. Rosen
AFA. Mark Fendrick
A. Mark Fendrick
When everyone is required to pay the same out-of-pocket amount for health care services whose benefits depend on patient characteristics, there is enormous potential for both under- and overuse. Unlike most current health plan designs, Value-Based Insurance Design (VBID) explicitly acknowledges and responds to patient heterogeneity. It encourages the use of services when the clinical benefits exceed the cost and likewise discourages the use of services when the benefits do not justify the cost. This paper makes the case for VBID and outlines current VBID initiatives in the private sector as well as barriers to further adoption.

1 January 2008 in Health Affairs
Verified
Journal Article
Closed access
MCMichael E. Chernew
Michael E. Chernew
MSMayur R. Shah
Mayur R. Shah
AWArnold Wegh
Arnold Wegh
SRStephen N. Rosenberg
Stephen N. Rosenberg
IJIver A. Juster
Iver A. Juster
AFA. Mark Fendrick
A. Mark Fendrick
This paper estimates the effects of a large employer's value-based insurance initiative designed to improve adherence to recommended treatment regimens. The intervention reduced copayments for five chronic medication classes in the context of a disease management (DM) program. Compared to a control employer that used the same DM program, adherence to medications in the value-based intervention increased for four of five medication classes, reducing nonadherence by 7-14 percent. The results demonstrate the potential for copayment reductions for highly valued services to increase medication adherence above the effects of existing DM programs.

29 April 2008 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
MCMichael Chernew
Michael Chernew
TGTeresa B. Gibson
Teresa B. Gibson
KYKristina Yu-Isenberg
Kristina Yu-Isenberg
MSMichael C. Sokol
Michael C. Sokol
ARAllison B. Rosen
Allison B. Rosen
AFA. Mark Fendrick
A. Mark Fendrick

1 January 2011 in Health Affairs
Verified
Journal Article
Closed access
MCMichael E. Chernew
Michael E. Chernew
RMRobert E. Mechanic
Robert E. Mechanic
BLBruce E. Landon
Bruce E. Landon
DSDana Gelb Safran
Dana Gelb Safran
In January 2009 Blue Cross Blue Shield of Massachusetts launched a new payment arrangement called the Alternative Quality Contract. The contract stipulates a modified global payment (fixed payments for the care of a patient during a specified time period) arrangement. The model differs from past models of fixed payments or capitation because it explicitly connects payments to achieving quality goals and defines the rate of increase for each contract group’s budget over a five-year period, unlike typical annual contracts. All groups participating in the Alternative Quality Contract earned significant quality bonuses in the first year. This arrangement exemplifies the type of experimentation encouraged by the Affordable Care Act. We describe this unique contract and show how it surmounts hurdles previously encountered with other global-payment models.

1 March 2010 in Health Affairs
Verified
Journal Article
Closed access
MCMichael E. Chernew
Michael E. Chernew
IJIver A. Juster
Iver A. Juster
MSMayur Shah
Mayur Shah
AWArnold Wegh
Arnold Wegh
SRStephen Rosenberg
Stephen Rosenberg
AFA. Mark Fendrick
A. Mark Fendrick
Value-based insurance design reduces patient copayments to encourage the use of health care services of high clinical value. As employers face constant pressure to control health care costs, this type of coverage has received much attention as a cost-savings device. This paper’s examination of one value-based insurance design program found that the program led to reduced use of nondrug health care services, offsetting the costs associated with additional use of drugs encouraged by the program. The findings suggest that value-based insurance design programs do not increase total systemwide medical spending.

1 September 2009 in Health Affairs
Verified
Journal Article
Closed access
PDF file
MCMichael E. Chernew
Michael E. Chernew
RHRichard A. Hirth
Richard A. Hirth
DCDavid M. Cutler
David M. Cutler
This paper updates one we published in 2003, describing the implications of continued health care spending growth for the consumption of nonhealth goods and services. Our estimates now show that at approximately long-run average rates of excess health spending growth, 119 percent of the real increase in per capita income would be devoted to health spending over the 2007–2083 projection period. We argue that an alternative scenario, under which health spending grew just one percentage point faster than real per capita income, is “affordable,” although 53.6 percent of real income growth over the period would go to health care. Moreover, even with the more favorable assumption, the nation would still face important challenges paying for care and dividing up the burden. This analysis thus supports the argument that reforms that would dramatically slow the rate of health care spending growth are necessary, especially if the nation hopes to maintain a reasonable amount of consumption of nonhealth goods and services.